Design Therapeutics is a clinical-stage biopharmaceutical company developing GeneTAC® molecules, a novel class of small-molecule compounds designed to treat inherited nucleotide repeat expansion diseases by selectively targeting and modulating disease-causing genetic mutations. The GeneTAC® platform uses a dual-mechanism approach combining DNA targeting and transcriptional engagement to either restore normal gene expression in diseases where repeat expansions impair protein production or reduce toxic gene products in diseases where expanded repeats generate harmful RNA and proteins. The company pursues a portfolio of lead programs across multiple indication areas including neurodegenerative and ophthalmologic diseases, with the goal of bringing disease-modifying therapeutics to market either through independent commercialization or strategic partnerships, while leveraging a broad patent estate and contract manufacturing relationships.